This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1998 Jan;26(1):186-7.

doi: 10.1086/517056.

The hidden danger of primary fluconazole prophylaxis for patients with AIDS

J Berg¹, C J Clancy, M H Nguyen

Affiliations

PMID: 9455533
DOI: 10.1086/517056

The hidden danger of primary fluconazole prophylaxis for patients with AIDS

J Berg et al. Clin Infect Dis. 1998 Jan.

. 1998 Jan;26(1):186-7.

doi: 10.1086/517056.

Authors

J Berg¹, C J Clancy, M H Nguyen

Affiliation

¹ Department of Medicine, University of Florida College of Medicine, Gainesville, USA.

PMID: 9455533
DOI: 10.1086/517056

No abstract available

PubMed Disclaimer

Similar articles

Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy.
Rollot F, Bossi P, Tubiana R, Caumes E, Zeller V, Katlama C, Bricaire F. Rollot F, et al. AIDS. 2001 Jul 27;15(11):1448-9. doi: 10.1097/00002030-200107270-00019. AIDS. 2001. PMID: 11504971 Clinical Trial. No abstract available.
Cessation of secondary prophylaxis in patients with cryptococcosis.
Nwokolo NC, Fisher M, Gazzard BG, Nelson MR. Nwokolo NC, et al. AIDS. 2001 Jul 27;15(11):1438-9. doi: 10.1097/00002030-200107270-00015. AIDS. 2001. PMID: 11504967
Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy.
Sungkanuparph S, Savetamornkul C, Pattanapongpaiboon W. Sungkanuparph S, et al. Clin Infect Dis. 2017 Apr 1;64(7):967-970. doi: 10.1093/cid/cix036. Clin Infect Dis. 2017. PMID: 28362939
[Fluconazole (Diflucan): its clinical spectrum and development].
Espejo Martínez J, Alvarez Medina MP, Sánchez Morales S. Espejo Martínez J, et al. Rev Clin Esp. 1997 Apr;197 Suppl 1:86-93. Rev Clin Esp. 1997. PMID: 9297211 Review. Spanish. No abstract available.
[Therapy of candidiasis and cryptococcosis in AIDS].
Just-Nübling G. Just-Nübling G. Mycoses. 1994;37 Suppl 2:56-63. Mycoses. 1994. PMID: 7609745 Review. German.

See all similar articles

Cited by

Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study.
Chen YC, Chang TY, Liu JW, Chen FJ, Chien CC, Lee CH, Lu CH. Chen YC, et al. BMC Infect Dis. 2015 Jul 22;15:277. doi: 10.1186/s12879-015-1023-8. BMC Infect Dis. 2015. PMID: 26194004 Free PMC article.
Heteroresistance of Cryptococcus gattii to fluconazole.
Varma A, Kwon-Chung KJ. Varma A, et al. Antimicrob Agents Chemother. 2010 Jun;54(6):2303-11. doi: 10.1128/AAC.00153-10. Epub 2010 Apr 12. Antimicrob Agents Chemother. 2010. PMID: 20385871 Free PMC article.
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.
Nguyen MH, Yu CY. Nguyen MH, et al. Antimicrob Agents Chemother. 1998 Feb;42(2):471-2. doi: 10.1128/AAC.42.2.471. Antimicrob Agents Chemother. 1998. PMID: 9527812 Free PMC article.
Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN. Yamazumi T, et al. J Clin Microbiol. 2003 Jan;41(1):267-72. doi: 10.1128/JCM.41.1.267-272.2003. J Clin Microbiol. 2003. PMID: 12517859 Free PMC article.
Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. Sionov E, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2804-15. doi: 10.1128/AAC.00295-09. Epub 2009 May 4. Antimicrob Agents Chemother. 2009. PMID: 19414582 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information